My Bibliography - NCBI

My Bibliography - NCBI
Skip to main page content
The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.
The site is secure.
The
ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.
Access keys
NCBI Homepage
MyNCBI Homepage
Main Content
Main Navigation
MyNCBI
selected
select all 65
clear all
65 citations,
Sort by
newest to oldest
recently updated
newest to oldest
oldest to newest
author
author
select
Pottenger AE, Roy D, Srinivasan S, Chavas TEJ, Vlaskin V, Ho DK, Livingston VC, Maktabi M, Lin H, Zhang J, Pybus B, Kudyba K, Roth A, Senter P, Tyson G, Huber HE, Wesche D, Rochford R, Burke PA, Stayton PS.
Liver-targeted polymeric prodrugs delivered subcutaneously improve tafenoquine therapeutic window for malaria radical cure.
Sci Adv
2024 Apr 19;
10
(16)
:eadk4492
doi: 10.1126/sciadv.adk4492.
Epub 2024 Apr 19.
PubMed PMID:
38640243
; PubMed Central PMCID:
PMC11029812
select
Srinivasan S, Roy D, Chavas TEJ, Vlaskin V, Ho DK, Pottenger A, LeGuyader CLM, Maktabi M, Strauch P, Jackson C, Flaherty SM, Lin H, Zhang J, Pybus B, Li Q, Huber HE, Burke PA, Wesche D, Rochford R, Stayton PS.
Liver-targeted polymeric prodrugs of 8-aminoquinolines for malaria radical cure.
J Control Release
2021 Mar 10;
331
:213-227
doi: 10.1016/j.jconrel.2020.12.046.
Epub 2020 Dec 27.
PubMed PMID:
33378692
select
Sarker D, Plummer R, Meyer T, Sodergren MH, Basu B, Chee CE, Huang KW, Palmer DH, Ma YT, Evans TRJ, Spalding DRC, Pai M, Sharma R, Pinato DJ, Spicer J, Hunter S, Kwatra V, Nicholls JP, Collin D, Nutbrown R, Glenny H, Fairbairn S, Reebye V, Voutila J, Dorman S, Andrikakou P, Lloyd P, Felstead S, Vasara J, Habib R, Wood C, Saetrom P, Huber HE, Blakey DC, Rossi JJ, Habib N.
MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial.
Clin Cancer Res
2020 Aug 1;
26
(15)
:3936-3946
doi: 10.1158/1078-0432.CCR-20-0414.
Epub 2020 May 1.
PubMed PMID:
32357963
select
Reebye V, Huang KW, Lin V, Jarvis S, Cutilas P, Dorman S, Ciriello S, Andrikakou P, Voutila J, Saetrom P, Mintz PJ, Reccia I, Rossi JJ, Huber H, Habib R, Kostomitsopoulos N, Blakey DC, Habib NA.
Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer.
Oncogene
2018 Jun;
37
(24)
:3216-3228
doi: 10.1038/s41388-018-0126-2.
Epub 2018 Mar 7.
PubMed PMID:
29511346
; PubMed Central PMCID:
PMC6013054
select
Voutila J, Reebye V, Roberts TC, Protopapa P, Andrikakou P, Blakey DC, Habib R, Huber H, Saetrom P, Rossi JJ, Habib NA.
Development and Mechanism of Small Activating RNA Targeting CEBPA, a Novel Therapeutic in Clinical Trials for Liver Cancer.
Mol Ther
2017 Dec 6;
25
(12)
:2705-2714
doi: 10.1016/j.ymthe.2017.07.018.
Epub 2017 Aug 4.
PubMed PMID:
28882451
; PubMed Central PMCID:
PMC5768526
select
Zhang N, Liu L, Dumitru CD, Cummings NR, Cukan M, Jiang Y, Li Y, Li F, Mitchell T, Mallem MR, Ou Y, Patel RN, Vo K, Wang H, Burnina I, Choi BK, Huber HE, Stadheim TA, Zha D.
Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study.
MAbs
2011 May-Jun;
(3)
:289-98
doi: 10.4161/mabs.3.3.15532.
Epub 2011 May 1.
PubMed PMID:
21487242
; PubMed Central PMCID:
PMC3149709
select
Cherrin C, Haskell K, Howell B, Jones R, Leander K, Robinson R, Watkins A, Bilodeau M, Hoffman J, Sanderson P, Hartman G, Mahan E, Prueksaritanont T, Jiang G, She QB, Rosen N, Sepp-Lorenzino L, Defeo-Jones D, Huber HE.
An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo.
Cancer Biol Ther
2010 Apr 1;
(7)
:493-503
doi: 10.4161/cbt.9.7.11100.
Epub 2010 Apr 1.
PubMed PMID:
20139722
; PubMed Central PMCID:
PMC2987445
select
Aste-Amézaga M, Zhang N, Lineberger JE, Arnold BA, Toner TJ, Gu M, Huang L, Vitelli S, Vo KT, Haytko P, Zhao JZ, Baleydier F, L'Heureux S, Wang H, Gordon WR, Thoryk E, Andrawes MB, Tiyanont K, Stegmaier K, Roti G, Ross KN, Franlin LL, Wang H, Wang F, Chastain M, Bett AJ, Audoly LP, Aster JC, Blacklow SC, Huber HE.
Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors.
PLoS One
2010 Feb 8;
(2)
:e9094
doi: 10.1371/journal.pone.0009094.
PubMed PMID:
20161710
; PubMed Central PMCID:
PMC2817004
select
Li Y, Liang J, Siu T, Hu E, Rossi MA, Barnett SF, Defeo-Jones D, Jones RE, Robinson RG, Leander K, Huber HE, Mittal S, Cosford N, Prasit P.
Allosteric inhibitors of Akt1 and Akt2: discovery of [1,2,4]triazolo[3,4-f][1,6]naphthyridines with potent and balanced activity.
Bioorg Med Chem Lett
2009 Feb 1;
19
(3)
:834-6
doi: 10.1016/j.bmcl.2008.12.017.
Epub 2008 Dec 7.
PubMed PMID:
19097777
select
She QB, Chandarlapaty S, Ye Q, Lobo J, Haskell KM, Leander KR, DeFeo-Jones D, Huber HE, Rosen N.
RETRACTED: Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.
PLoS One
2008 Aug 26;
(8)
:e3065
doi: 10.1371/journal.pone.0003065.
PubMed PMID:
18725974
; PubMed Central PMCID:
PMC2516933
select
Cox CD, Coleman PJ, Breslin MJ, Whitman DB, Garbaccio RM, Fraley ME, Buser CA, Walsh ES, Hamilton K, Schaber MD, Lobell RB, Tao W, Davide JP, Diehl RE, Abrams MT, South VJ, Huber HE, Torrent M, Prueksaritanont T, Li C, Slaughter DE, Mahan E, Fernandez-Metzler C, Yan Y, Kuo LC, Kohl NE, Hartman GD.
Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-n-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory cancer.
J Med Chem
2008 Jul 24;
51
(14)
:4239-52
doi: 10.1021/jm800386y.
Epub 2008 Jun 25.
PubMed PMID:
18578472
select
Bilodeau MT, Balitza AE, Hoffman JM, Manley PJ, Barnett SF, Defeo-Jones D, Haskell K, Jones RE, Leander K, Robinson RG, Smith AM, Huber HE, Hartman GD.
Allosteric inhibitors of Akt1 and Akt2: a naphthyridinone with efficacy in an A2780 tumor xenograft model.
Bioorg Med Chem Lett
2008 Jun 1;
18
(11)
:3178-82
doi: 10.1016/j.bmcl.2008.04.074.
Epub 2008 May 1.
PubMed PMID:
18479914
select
Wu Z, Hartnett JC, Neilson LA, Robinson RG, Fu S, Barnett SF, Defeo-Jones D, Jones RE, Kral AM, Huber HE, Hartman GD, Bilodeau MT.
Development of pyridopyrimidines as potent Akt1/2 inhibitors.
Bioorg Med Chem Lett
2008 Feb 15;
18
(4)
:1274-9
doi: 10.1016/j.bmcl.2008.01.054.
Epub 2008 Jan 19.
PubMed PMID:
18249537
select
Hartnett JC, Barnett SF, Bilodeau MT, Defeo-Jones D, Hartman GD, Huber HE, Jones RE, Kral AM, Robinson RG, Wu Z.
Optimization of 2,3,5-trisubstituted pyridine derivatives as potent allosteric Akt1 and Akt2 inhibitors.
Bioorg Med Chem Lett
2008 Mar 15;
18
(6)
:2194-7
doi: 10.1016/j.bmcl.2007.12.040.
Epub 2007 Dec 23.
PubMed PMID:
18294842
select
Zhao Z, Robinson RG, Barnett SF, Defeo-Jones D, Jones RE, Hartman GD, Huber HE, Duggan ME, Lindsley CW.
Development of potent, allosteric dual Akt1 and Akt2 inhibitors with improved physical properties and cell activity.
Bioorg Med Chem Lett
2008 Jan 1;
18
(1)
:49-53
doi: 10.1016/j.bmcl.2007.11.015.
Epub 2007 Nov 13.
PubMed PMID:
18054229
select
Wu Z, Robinson RG, Fu S, Barnett SF, Defeo-Jones D, Jones RE, Kral AM, Huber HE, Kohl NE, Hartman GD, Bilodeau MT.
Rapid assembly of diverse and potent allosteric Akt inhibitors.
Bioorg Med Chem Lett
2008 Mar 15;
18
(6)
:2211-4
doi: 10.1016/j.bmcl.2007.10.023.
Epub 2007 Oct 17.
PubMed PMID:
18296048
select
Garbaccio RM, Tasber ES, Neilson LA, Coleman PJ, Fraley ME, Olson C, Bergman J, Torrent M, Buser CA, Rickert K, Walsh ES, Hamilton K, Lobell RB, Tao W, South VJ, Diehl RE, Davide JP, Yan Y, Kuo LC, Li C, Prueksaritanont T, Fernandez-Metzler C, Mahan EA, Slaughter DE, Salata JJ, Kohl NE, Huber HE, Hartman GD.
Kinesin spindle protein (KSP) inhibitors. Part 7: Design and synthesis of 3,3-disubstituted dihydropyrazolobenzoxazines as potent inhibitors of the mitotic kinesin KSP.
Bioorg Med Chem Lett
2007 Oct 15;
17
(20)
:5671-6
doi: 10.1016/j.bmcl.2007.07.067.
Epub 2007 Aug 21.
PubMed PMID:
17804233
select
Cox CD, Breslin MJ, Whitman DB, Coleman PJ, Garbaccio RM, Fraley ME, Zrada MM, Buser CA, Walsh ES, Hamilton K, Lobell RB, Tao W, Abrams MT, South VJ, Huber HE, Kohl NE, Hartman GD.
Kinesin spindle protein (KSP) inhibitors. Part V: discovery of 2-propylamino-2,4-diaryl-2,5-dihydropyrroles as potent, water-soluble KSP inhibitors, and modulation of their basicity by beta-fluorination to overcome cellular efflux by P-glycoprotein.
Bioorg Med Chem Lett
2007 May 15;
17
(10)
:2697-702
doi: 10.1016/j.bmcl.2007.03.006.
Epub 2007 Mar 6.
PubMed PMID:
17395460
select
Fraley ME, Garbaccio RM, Arrington KL, Hoffman WF, Tasber ES, Coleman PJ, Buser CA, Walsh ES, Hamilton K, Fernandes C, Schaber MD, Lobell RB, Tao W, South VJ, Yan Y, Kuo LC, Prueksaritanont T, Shu C, Torrent M, Heimbrook DC, Kohl NE, Huber HE, Hartman GD.
Kinesin spindle protein (KSP) inhibitors. Part 2: the design, synthesis, and characterization of 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP.
Bioorg Med Chem Lett
2006 Apr 1;
16
(7)
:1775-9
doi: 10.1016/j.bmcl.2006.01.030.
Epub 2006 Jan 24.
PubMed PMID:
16439123
select
Garbaccio RM, Fraley ME, Tasber ES, Olson CM, Hoffman WF, Arrington KL, Torrent M, Buser CA, Walsh ES, Hamilton K, Schaber MD, Fernandes C, Lobell RB, Tao W, South VJ, Yan Y, Kuo LC, Prueksaritanont T, Slaughter DE, Shu C, Heimbrook DC, Kohl NE, Huber HE, Hartman GD.
Kinesin spindle protein (KSP) inhibitors. Part 3: synthesis and evaluation of phenolic 2,4-diaryl-2,5-dihydropyrroles with reduced hERG binding and employment of a phosphate prodrug strategy for aqueous solubility.
Bioorg Med Chem Lett
2006 Apr 1;
16
(7)
:1780-3
doi: 10.1016/j.bmcl.2005.12.094.
Epub 2006 Jan 24.
PubMed PMID:
16439122
select
Cox CD, Breslin MJ, Mariano BJ, Coleman PJ, Buser CA, Walsh ES, Hamilton K, Huber HE, Kohl NE, Torrent M, Yan Y, Kuo LC, Hartman GD.
Kinesin spindle protein (KSP) inhibitors. Part 1: The discovery of 3,5-diaryl-4,5-dihydropyrazoles as potent and selective inhibitors of the mitotic kinesin KSP.
Bioorg Med Chem Lett
2005 Apr 15;
15
(8)
:2041-5
doi: 10.1016/j.bmcl.2005.02.055.
PubMed PMID:
15808464
select
Zhao Z, Leister WH, Robinson RG, Barnett SF, Defeo-Jones D, Jones RE, Hartman GD, Huff JR, Huber HE, Duggan ME, Lindsley CW.
Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors.
Bioorg Med Chem Lett
2005 Feb 15;
15
(4)
:905-9
doi: 10.1016/j.bmcl.2004.12.062.
PubMed PMID:
15686884
select
Lindsley CW, Zhao Z, Leister WH, Robinson RG, Barnett SF, Defeo-Jones D, Jones RE, Hartman GD, Huff JR, Huber HE, Duggan ME.
Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors.
Bioorg Med Chem Lett
2005 Feb 1;
15
(3)
:761-4
doi: 10.1016/j.bmcl.2004.11.011.
PubMed PMID:
15664853
select
DeFeo-Jones D, Barnett SF, Fu S, Hancock PJ, Haskell KM, Leander KR, McAvoy E, Robinson RG, Duggan ME, Lindsley CW, Zhao Z, Huber HE, Jones RE.
Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members.
Mol Cancer Ther
2005 Feb;
(2)
:271-9
PubMed PMID:
15713898
select
Barnett SF, Defeo-Jones D, Fu S, Hancock PJ, Haskell KM, Jones RE, Kahana JA, Kral AM, Leander K, Lee LL, Malinowski J, McAvoy EM, Nahas DD, Robinson RG, Huber HE.
Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors.
Biochem J
2005 Jan 15;
385
(Pt 2)
:399-408
doi: 10.1042/BJ20041140.
PubMed PMID:
15456405
; PubMed Central PMCID:
PMC1134710
select
Dinsmore CJ, Zartman CB, Bergman JM, Abrams MT, Buser CA, Culberson JC, Davide JP, Ellis-Hutchings M, Fernandes C, Graham SL, Hartman GD, Huber HE, Lobell RB, Mosser SD, Robinson RG, Williams TM.
Macrocyclic piperazinones as potent dual inhibitors of farnesyltransferase and geranylgeranyltransferase-I.
Bioorg Med Chem Lett
2004 Feb 9;
14
(3)
:639-43
doi: 10.1016/j.bmcl.2003.11.051.
PubMed PMID:
14741259
select
Yan Y, Sardana V, Xu B, Homnick C, Halczenko W, Buser CA, Schaber M, Hartman GD, Huber HE, Kuo LC.
Inhibition of a mitotic motor protein: where, how, and conformational consequences.
J Mol Biol
2004 Jan 9;
335
(2)
:547-54
doi: 10.1016/j.jmb.2003.10.074.
PubMed PMID:
14672662
select
deSolms SJ, Ciccarone TM, MacTough SC, Shaw AW, Buser CA, Ellis-Hutchings M, Fernandes C, Hamilton KA, Huber HE, Kohl NE, Lobell RB, Robinson RG, Tsou NN, Walsh ES, Graham SL, Beese LS, Taylor JS.
Dual protein farnesyltransferase-geranylgeranyltransferase-I inhibitors as potential cancer chemotherapeutic agents.
J Med Chem
2003 Jul 3;
46
(14)
:2973-84
doi: 10.1021/jm020587n.
PubMed PMID:
12825937
select
Tucker TJ, Abrams MT, Buser CA, Davide JP, Ellis-Hutchings M, Fernandes C, Gibbs JB, Graham SL, Hartman GD, Huber HE, Liu D, Lobell RB, Lumma WC, Robinson RG, Sisko JT, Smith AM.
The synthesis and biological evaluation of a series of potent dual inhibitors of farnesyl and geranyl-Geranyl protein transferases.
Bioorg Med Chem Lett
2002 Aug 5;
12
(15)
:2027-30
doi: 10.1016/s0960-894x(02)00308-6.
PubMed PMID:
12113834
select
Bell IM, Gallicchio SN, Abrams M, Beese LS, Beshore DC, Bhimnathwala H, Bogusky MJ, Buser CA, Culberson JC, Davide J, Ellis-Hutchings M, Fernandes C, Gibbs JB, Graham SL, Hamilton KA, Hartman GD, Heimbrook DC, Homnick CF, Huber HE, Huff JR, Kassahun K, Koblan KS, Kohl NE, Lobell RB, Lynch JJ Jr, Robinson R, Rodrigues AD, Taylor JS, Walsh ES, Williams TM, Zartman CB.
3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency.
J Med Chem
2002 Jun 6;
45
(12)
:2388-409
doi: 10.1021/jm010531d.
PubMed PMID:
12036349
select
Nguyen DN, Stump CA, Walsh ES, Fernandes C, Davide JP, Ellis-Hutchings M, Robinson RG, Williams TM, Lobell RB, Huber HE, Buser CA.
Potent inhibitors of farnesyltransferase and geranylgeranyltransferase-I.
Bioorg Med Chem Lett
2002 May 6;
12
(9)
:1269-73
doi: 10.1016/s0960-894x(02)00154-3.
PubMed PMID:
11965368
select
Gibbs J, Anthony N, Bell I, Huber HE, Williams T.
Farnesyltransferase inhibitors as potential anticancer agents..
In:
Ojima I, Vite GD, Altman KH, editors.
Anticancer Agents
Washington, D.C.: American Chemical Society;
2001.
11-17p.
select
Heimbrook D, Huber H, Koblan K, Kohil N, Lobelll R, Williams T.
JB Gibbs1, NJ Anthony2, 1. Bell2, CA Buser1, JP Davidel.
Anticancer Agents: Frontiers in Cancer Chemotherapy.
2001
(796)
:190
select
Beshore DC, Bell IM, Dinsmore CJ, Homnick CF, Culberson JC, Robinson RG, Fernandes C, Walsh ES, Abrams MT, Bhimnathwala HG, Davide JP, Ellis-Hutchings MS, Huber HA, Koblan KS, Buser CA, Kohl NE, Lobell RB, Chen IW, McLoughlin DA, Olah TV, Graham SL, Hartman GD, Williams TM.
Evaluation of amino acid-based linkers in potent macrocyclic inhibitors of farnesyl-protein transferase.
Bioorg Med Chem Lett
2001 Jul 23;
11
(14)
:1817-21
doi: 10.1016/s0960-894x(01)00340-7.
PubMed PMID:
11459639
select
Bergman JM, Abrams MT, Davide JP, Greenberg IB, Robinson RG, Buser CA, Huber HE, Koblan KS, Kohl NE, Lobell RB, Graham SL, Hartman GD, Williams TM, Dinsmore CJ.
Aryloxy substituted N-arylpiperazinones as dual inhibitors of farnesyltransferase and geranylgeranyltransferase-I.
Bioorg Med Chem Lett
2001 Jun 4;
11
(11)
:1411-5
doi: 10.1016/s0960-894x(01)00240-2.
PubMed PMID:
11378366
select
Trotter BW, Quigley AG, Lumma WC, Sisko JT, Walsh ES, Hamann CS, Robinson RG, Bhimnathwala H, Kolodin DG, Zheng W, Buser CA, Huber HE, Lobell RB, Kohl NE, Williams TM, Graham SL, Dinsmore CJ.
2-Arylindole-3-acetamides: FPP-competitive inhibitors of farnesyl protein transferase.
Bioorg Med Chem Lett
2001 Apr 9;
11
(7)
:865-9
doi: 10.1016/s0960-894x(01)00061-0.
PubMed PMID:
11294379
select
Huber HE, Robinson RG, Watkins A, Nahas DD, Abrams MT, Buser CA, Lobell RB, Patrick D, Anthony NJ, Dinsmore CJ, Graham SL, Hartman GD, Lumma WC, Williams TM, Heimbrook DC.
Anions modulate the potency of geranylgeranyl-protein transferase I inhibitors.
J Biol Chem
2001 Jul 6;
276
(27)
:24457-65
doi: 10.1074/jbc.M100325200.
Epub 2001 Mar 26.
PubMed PMID:
11274181
select
Dinsmore CJ, Bogusky MJ, Culberson JC, Bergman JM, Homnick CF, Zartman CB, Mosser SD, Schaber MD, Robinson RG, Koblan KS, Huber HE, Graham SL, Hartman GD, Huff JR, Williams TM.
Conformational restriction of flexible ligands guided by the transferred noe experiment: potent macrocyclic inhibitors of farnesyltransferase.
J Am Chem Soc
2001 Mar 7;
123
(9)
:2107-8
doi: 10.1021/ja003673q.
PubMed PMID:
11456854
select
Zhao A, Lee SH, Mojena M, Jenkins RG, Patrick DR, Huber HE, Goetz MA, Hensens OD, Zink DL, Vilella D, Dombrowski AW, Lingham RB, Huang L.
Resorcylic acid lactones: naturally occurring potent and selective inhibitors of MEK.
J Antibiot (Tokyo)
1999 Dec;
52
(12)
:1086-94
doi: 10.7164/antibiotics.52.1086.
PubMed PMID:
10695671
select
Huang PS, Davis L, Huber H, Goodhart PJ, Wegrzyn RE, Oliff A, Heimbrook DC.
An SH3 domain is required for the mitogenic activity of microinjected phospholipase C-gamma 1.
FEBS Lett
1995 Jan 30;
358
(3)
:287-92
doi: 10.1016/0014-5793(94)01453-8.
PubMed PMID:
7843417
select
Huber H, Koblan K, Heimbrook D.
Protein-protein interactions as therapeutic targets for cancer.
Current medicinal chemistry.
1994
(1)
:13-34
select
Huber HE, Goodhart PJ, Huang PS.
Retinoblastoma protein reverses DNA bending by transcription factor E2F.
J Biol Chem
1994 Mar 4;
269
(9)
:6999-7005
PubMed PMID:
8120063
select
Ivey-Hoyle M, Conroy R, Huber HE, Goodhart PJ, Oliff A, Heimbrook DC.
Cloning and characterization of E2F-2, a novel protein with the biochemical properties of transcription factor E2F.
Mol Cell Biol
1993 Dec;
13
(12)
:7802-12
doi: 10.1128/mcb.13.12.7802-7812.1993.
PubMed PMID:
8246995
; PubMed Central PMCID:
PMC364852
select
Huber HE, Edwards G, Goodhart PJ, Patrick DR, Huang PS, Ivey-Hoyle M, Barnett SF, Oliff A, Heimbrook DC.
Transcription factor E2F binds DNA as a heterodimer.
Proc Natl Acad Sci U S A
1993 Apr 15;
90
(8)
:3525-9
doi: 10.1073/pnas.90.8.3525.
PubMed PMID:
8475102
; PubMed Central PMCID:
PMC46333
select
Huang PS, Patrick DR, Edwards G, Goodhart PJ, Huber HE, Miles L, Garsky VM, Oliff A, Heimbrook DC.
Protein domains governing interactions between E2F, the retinoblastoma gene product, and human papillomavirus type 16 E7 protein.
Mol Cell Biol
1993 Feb;
13
(2)
:953-60
doi: 10.1128/mcb.13.2.953-960.1993.
PubMed PMID:
7678696
; PubMed Central PMCID:
PMC358979
select
Stirdivant SM, Huber HE, Patrick DR, Defeo-Jones D, McAvoy EM, Garsky VM, Oliff A, Heimbrook DC.
Human papillomavirus type 16 E7 protein inhibits DNA binding by the retinoblastoma gene product.
Mol Cell Biol
1992 May;
12
(5)
:1905-14
doi: 10.1128/mcb.12.5.1905-1914.1992.
PubMed PMID:
1314947
; PubMed Central PMCID:
PMC364344
select
Edwards GM, Huber HE, DeFeo-Jones D, Vuocolo G, Goodhart PJ, Maigetter RZ, Sanyal G, Oliff A, Heimbrook DC.
Purification and characterization of a functionally homogeneous 60-kDa species of the retinoblastoma gene product.
J Biol Chem
1992 Apr 25;
267
(12)
:7971-4
PubMed PMID:
1569054
select
Jones RE, Heimbrook DC, Huber HE, Wegrzyn RJ, Rotberg NS, Stauffer KJ, Lumma PK, Garsky VM, Oliff A.
Specific N-methylations of HPV-16 E7 peptides alter binding to the retinoblastoma suppressor protein.
J Biol Chem
1992 Jan 15;
267
(2)
:908-12
PubMed PMID:
1309779
select
Defeo-Jones D, Huang PS, Jones RE, Haskell KM, Vuocolo GA, Hanobik MG, Huber HE, Oliff A.
Cloning of cDNAs for cellular proteins that bind to the retinoblastoma gene product.
Nature
1991 Jul 18;
352
(6332)
:251-4
doi: 10.1038/352251a0.
PubMed PMID:
1857421
select
Huber HE, Richardson CC.
Processing of the primer for plus strand DNA synthesis by human immunodeficiency virus 1 reverse transcriptase.
J Biol Chem
1990 Jun 25;
265
(18)
:10565-73
PubMed PMID:
1693920
What would you like to do?
Append to existing collection
Create a new collection
Collection name:
Choose a collection: